System and method for personalized dosing of pharmacologic agents

• US 9,852,267 B2
• Filed: 09/28/2012
• Issued: 12/26/2017
• Est. Priority Date: 09/30/2011
• Status: Active Grant

• Current Assignee: University of Louisville
• Original Assignee: University of Louisville
• Inventors: Gaweda, Adam E., Brier, Michael E., Aronoff, George R., Jacobs, Alfred A.
• Primary Examiner(s): Lam, Eliza
• Application Number:
  US13/631,112
• Publication Number:
  US 20130085772A1
• Time in Patent Office: 1,915 Days
• Field of Search: 705 2- 3
• CPC Class Codes: A61B 34/10 Computer-aided planning, simulation or modelling of surgical operations
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders
• CPC Class Codes: G16Z 99/00 Subject matter not provided for in other main groups of this subclass

Abstract

A system and method for personalized dosing of a pharmacologic agent include: executing, using a processing device, a plurality of dosing regimen program modules to determine a respective plurality of dose sets in response to receiving, from an input device, a target response value for a patient; and executing, using the processing device, a dosing selection algorithm module, following executing the plurality of dosing regimen program modules and in response to receiving from the input device a response profile and a monitoring frequency of the patient, to determine a recommended dose set computed as a combination of the plurality of dose sets weighted by degrees of matching computed using fuzzy sets and the response profile.

Claims

1. A method for treating anemia in a subject using erythropoietic stimulating agents (Epo), comprising:

obtaining a target hemoglobin value (Hb_target), a current hemoglobin value (Hb_k), a rate of change of hemoglobin value (Δ

Hb_k), and an Epo dose received value (Epo_k) related to an amount of Epo being received by the subject;

determining an initial recommended Epo dose (Epo_k+1,i*) for each of i dosing regimens based on the target hemoglobin value (Hb_target), the current hemoglobin value (Hb_k), the rate of change of hemoglobin value (Δ

Hb_k), and the previous Epo dose prescribed value (Epo_k);

determining a next recommended Epo dose (Epo_k+1) based on the initial recommended Epo doses for the i dosing regimens weighted by degrees of matching computed using fuzzy membership functions;

determining, using a dose-response model, a Hb_k+1 value and a predicted hemoglobin response value (Δ

Hb_k+1) for a subject with a respective Epo sensitivity profile based on the Hb_k value, the Δ

Hb_k value, and a proposed Epo_k+1 value;

determining, using an optimization algorithm, the Epo_k+1,i* value by determining the proposed Epo_k+1 value using the Hb_target value, the Epo_k value, the Hb_k+1 value and the Δ

Hb_k+1 value, and then iteratively re-determining the proposed Epo_k+1 value until the proposed Epo_k+1 values converge to the Epo_k+1,i* value; and

administering the next recommended Epo dose to the subject;

wherein the dose-response model is substantially according to the function;

2. A method for treating anemia in a subject using erythropoietic stimulating agents (Epo), comprising:

obtaining a target hemoglobin value (Hb_target), a current hemoglobin value (Hb_k), a rate of change of hemoglobin value (Δ

Hb_k), and an Epo dose received value (Epo_k) related to an amount of Epo being received by the subject;

determining an initial recommended Epo dose (Epo_k+1,i*) for each of i dosing regimens based on the target hemoglobin value (Hb_target), the current hemoglobin value (Hb_k), the rate of change of hemoglobin value (Δ

Hb_k), and the previous Epo dose prescribed value (Epo_k);

determining a next recommended Epo dose (Epo_k+1) based on the initial recommended Epo doses for the i dosing regimens weighted by degrees of matching computed using fuzzy membership functions;

determining, using a dose-response model, a Hb_k+1 value and a predicted hemoglobin response value (Δ

Hb_k+1) for a subject with a respective Epo sensitivity profile based on the Hb_k value, the Δ

Hb_k value, and a proposed Epo_k+1 value; and

determining, using an optimization algorithm, the Epo_k+1,i* value by determining the proposed Epo_k+1 value using the Hb_target value, the Epo_k value, the Hb_k+1 value and the Δ

Hb_k+1 value, and then iteratively re-determining the proposed Epo_k+1 value until the proposed Epo_k+1 values converge to the Epo_k+1,i* value; and

administering the next recommended Epo dose to the subject;

wherein “

i”

equals 5 such that there are 5 dosing regimens; and

wherein Epo_k+1 is determined substantially according to the equation;